CGRP Education & Research Forum
Already a member? Become a member Register


Our slide decks bring together extensive clinical trial data supporting the efficacy and safety of the CGRP monoclonal antibodies, erenumab, fremanezumab, galcanezumab and eptinezumab, and the CGRP receptor antagonists (gepants), ubrogepant, rimegepant and atogepant.

Migraine care in Brazil: the role of anti-CGRP therapies is a new slide deck summarising clinical trial and real-world data, with links to key references. Although focusing on use of CGRP monoclonal antibodies in Brazil, it includes an update of key clinical results with erenumab, fremanezumab, galcanezumab and eptinezumab that is relevant to clinicians around the world who are treating migraine.

Migraine care in Brazil: the role of anti-CGRP therapiesMigraine care in Brazil: the role of anti-CGRP therapiesAtogepantAtogepantErenumabErenumabEptinezumabEptinezumabGalcanezumabGalcanezumabFremanezumabFremanezumabRimegepantRimegepantUbrogepantUbrogepant
Take a look at the background slides here >